BMC Oral Health

Short implants at 10 years: viable for the atrophic ridge, but survival stays below standard implants

Lin L, Ren Y, Zhu E

Source study: Ten-year outcomes of short dental implants (≤ 6 mm): a systematic review and sensitivity meta-analysis. — BMC Oral Health

In brief

  • Pooled 10-year survival was 91–94% (patient/implant level); sensitivity analysis returned the more conservative 89.7–92.8%.
  • Compared head-to-head with long implants in RCTs, short implants showed significantly lower survival (RR ~0.92–0.94), though complication rates and marginal bone loss did not differ significantly.
  • Marginal bone loss over a decade was modest at ~0.28 mm; peri-implantitis incidence was low at 0.4%, though peri-implant mucositis reached 33.6%.
  • Evidence base remains narrow — only 8 studies qualified; authors urge caution in extrapolating conclusions to clinical practice.

Short implants promise to sidestep bone grafting in the atrophic jaw. The open question has always been time: do they hold at ten years? This systematic review and meta-analysis gathered randomized controlled trials (RCTs) and prospective studies on implants of 6 mm or less with a full decade of follow-up, searching four databases and registered on PROSPERO. Eight studies qualified, four of them RCTs.

The pooled 10-year survival was 91.2% at the patient level and 93.7% at the implant level; sensitivity analysis, handling missing data by interpolation, returned the slightly more conservative 89.7% and 92.8%. Marginal bone loss (MBL) over ten years was modest, about 0.28 mm. Biological complications were dominated by peri-implant mucositis at 33.6%, while frank peri-implantitis stayed at 0.4%; technical complications ran at 23.5%, and screw-retained restorations survived less well than cemented ones. The head-to-head RCT comparison delivered the nuance: short implants survived significantly less than long implants (relative risk around 0.92-0.94), yet showed no significant difference in complications or bone loss.

So short implants are a viable long-term option for the atrophic ridge, sparing the patient augmentation, but their survival sits slightly below standard implants and the authors flag the small evidence base. A reasonable reading: a sound choice when grafting is best avoided, chosen with eyes open rather than as a free lunch.

Why it matters in practice

For clinicians managing atrophic ridges where augmentation carries higher risk or the patient declines grafting, this review supports short implants as a defensible long-term option — but the survival gap versus standard implants, while modest, is real and statistically significant, so patient selection and informed consent should reflect that trade-off explicitly.

This summary is automatically generated from the original abstract and curated by Dr. Ernesto Bruschi. Always refer to the original publication for clinical decisions.
Read original article ↗View on PubMed ↗

Related articles